Ichor Biologics (Ichor) is a pre-clinical biotechnology company having developed a novel platform for the isolation of naturally-occurring human monoclonal antibodies (Abs) against infectious diseases - effectively addressing leveraging natural human resistance to infectious disease. The firm's platform that exploits the evolution of human resistance to infectious diseases by identifying the immunological signatures associated with protection - enabling development of the antibodies that mimic those protective signatures: antibodies can then be used as therapeutics to confer protection in individuals that have succumb to disease states. Management indicate intent to utilize this platform to accelerate therapeutic development in the infectious disease space by rapidly producing Antibody-based therapeutics, which possess high safety and clinical efficacy profiles. The speed and efficacy of the platform will be utilized to produce Antibody-related intellectual property (IP) through the preclinical validation stage. In turn, that IP will be leveraged to establish strategic partnerships or licensing deals to engage industry partners, inturn providing access to clinical trial pipelines. ?
